designing the drugs of tomorrow
DaTaMabs Limited is a
semi-virtual antibody engineering "design house"
invents and creates humanized antibody sequences for its collaborators, using the
skills and experience of its Scientific Founders, Tarran Jones and David Williams.
DaTaMabs provides a royalty-free design service tailored to meet your needs, expertise and budget.
DaTaMabs draws on 40 man-years of know-how and experience in the genetic manipulation and recombinant expression of therapeutic antibody candidates.
Crucially, following the design phase, DaTaMabs continues to provide support, enabling collaborators efficiently to generate humanized antibody constructs, characterize their potency and select lead candidates.
DaTaMabs gives you ready access to the original, clinically-proven antibody humanization technology, CDR grafting. This process reliably removes immunogenicity issues whilst retaining potency and specificity.
The Founders of DaTaMabs have successfully humanized around 40 therapeutic antibody candidates in commercial collaborations with more than 20 biotech and pharma companies. These projects have led to the development of more than 10 clinical candidates, most of which are still in clinical trials.
Two further humanised antibodies (Tysabri and Actemra) have achieved market approval worldwide, whilst a third (Vedolizumab) is awaiting approval in the US and Europe.